Celladon Secures $30 Million in Series B Financing
07 12월 2005 - 11:00PM
PR Newswire (US)
Funding Will Support Clinical Development of Heart Failure Product
LA JOLLA, Calif., Dec. 7 /PRNewswire/ -- Celladon Corporation, a
biotechnology company developing treatments for heart failure and
other cardiovascular diseases, announced today that it had raised
$30 million in a Series B venture financing. The funding will
enable Celladon to complete preclinical testing and advance
MYDICAR(TM), its product to improve calcium handling in failing
hearts, toward Phase 1/2 clinical trials. New investors Kleiner
Perkins Caufield & Byers and Domain Associates led the round.
Existing investors Enterprise Partners Venture Capital and Venrock
Associates also participated. Dr. Jesse Treu, General Partner of
Domain, and Joseph Lacob, General Partner of Kleiner Perkins, have
joined Celladon's Board of Directors. "The investment in Celladon
by such high quality investors is testimony to the strong potential
of our product and the remarkable progress our team has made since
the company was founded 12 months ago," said Celladon Chairman Drew
Senyei. "In large animal models of heart failure, MYDICAR(TM) has
shown encouraging results. This Series B financing gives us an
experienced board and the resources to move the product toward the
clinic." "This financing will support development of Celladon's
MYDICAR(TM) gene therapy system, which enhances SERCA2a, an
important regulator of myocardial contractility," said Krisztina
Zsebo, Celladon's CEO. The SERCA2a gene construct is inserted in
Adeno-Associated Virus (AAV) vectors and delivered to the heart
percutaneously using a closed-loop oxygenated system. Celladon
Corporation is collaborating with Targeted Genetics Corporation
(NASDAQ:TGEN) on AAV-based manufacturing and gene product
development; and with The Baker Heart Research Institute and
V-Kardia, Inc. in development of a percutaneous delivery system.
About Celladon Celladon Corporation is a molecular cardiology
company based in La Jolla, California. The company's first product,
MYDICAR(TM), combines a gene based therapy with novel percutaneous
delivery to enhance calcium cycling in the hearts of patients with
congestive heart failure. DATASOURCE: Celladon Corporation CONTACT:
Krisztina Zsebo, Ph.D., CEO of Celladon Corporation,
+1-858-366-4288 Web site: http://www.celladon.net/
Copyright
Tecogen (NASDAQ:TGEN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Tecogen (NASDAQ:TGEN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024